For the treatment of autoimmune diseases, both the use of recombinant IFN-γ and antibodies against IFN-γ (e.g., fontolizumab) have been considered, perfectly illustrating the dual role of the cytokine in these disorders [120,121,122,123,124]. This evidence concerns the gene IFNG and autoimmune disease.